Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain–Barré syndrome: a possible prognostic biomarker for disability at 12 months

Key Points

• The study aims to evaluate the potential of cerebrospinal fluid alpha-internexin concentrations as a prognostic biomarker for disability in Guillain-Barré syndrome.
• Measured cerebrospinal fluid alpha-internexin concentrations at diagnosis.
• Evaluated long-term outcomes after 12 months.
• Assessed the relationship between CSF AINX levels and patient recovery.
• Elevated CSF alpha-internexin concentrations at diagnosis correlated with poorer long-term outcomes.
• High levels suggest potential CNS-related injury influencing recovery.

Abstract